Antibody-drug Conjugates (ADC)

Ala-Ala-Ala-NH-CH2OCH2COOH is an antibody-drug conjugate (ADC) linker that functions as an intermediate in ADC synthesis. This compound facilitates the conjugation of cytotoxic drugs to antibodies, enhancing the selectivity and efficacy of targeted cancer therapies. Its structure promotes stability and efficacy in various biological applications, making it a valuable tool in drug development and research.

4-DTM-phenoxy-PEG3-CH2COOH is a cleavable PEG-based linker specifically designed for antibody-drug conjugate (ADC) applications. This compound facilitates the attachment of therapeutic agents to antibodies, enhancing targeted delivery to cancer cells. Its chemical design allows for effective drug release upon internalization, making it a valuable tool for cancer research and therapeutic development.

Bis-(PEG6-acid)-SS is a cleavable linker designed for use in antibody-drug conjugates (ADCs), targeting the efficient delivery of cytotoxic agents to cancer cells. This 6 unit polyethylene glycol (PEG) moiety enhances solubility and stability while facilitating the controlled release of the attached drug through enzyme-mediated cleavage. It is an essential reagent for researchers developing optimized ADC therapies in cancer research and drug development.

Azide-PEG12-Val-Arg-PAB serves as an ADC linker, facilitating the conjugation of antibody-drug pairs. It is characterized by its unique valine-arginine scaffold, enhancing the stability and effectiveness of antibody-drug conjugates (ADCs). This compound is essential for the development and optimization of therapeutic ADC formulations in cancer research and targeted therapy.

DMAC-SPP is a cleavable linker designed for the synthesis of antibody-drug conjugates (ADCs). It facilitates targeted delivery of cytotoxic agents to cancer cells by releasing the drug in response to specific intracellular conditions. This reagent is essential for enhancing the efficacy and selectivity of ADCs in therapeutic applications, contributing to advancements in cancer treatment research.

m-PEG7-MS is a polyethylene glycol (PEG)-based linker designed for use in the synthesis of PROTACs and antibody-drug conjugates (ADCs). This cleavable linker facilitates the development of targeted therapeutics by enabling controlled release of active compounds. Its versatile application supports research in targeted protein degradation and drug delivery systems, making it an essential reagent for advancing science in cancer therapy and other diseases.

Fmoc-Gly-Gly-Phe-OtBu is a cleavable linker that facilitates the formation of antibody-drug conjugates (ADCs). This reagent provides a stable connection between antibodies and cytotoxic drugs, enabling targeted delivery to cancer cells. Its design enhances the therapeutic efficacy of ADCs while minimizing off-target effects, making it a valuable tool in the development of novel cancer therapies.

DBCO-NHCO-PEG4-NHS ester is a versatile linker designed for use in the synthesis of PROTACs and antibody-drug conjugates (ADCs). This PEG/alkyl/ether-based compound features a DBCO moiety that facilitates strain-promoted alkyne-azide cycloaddition (SPAAC) with azide-containing molecules. Its cleavable nature enhances the functionality and targeting capabilities of therapeutic agents, making it essential for researchers involved in drug development and bioconjugation applications.

Mal-Amide-PEG4-Val-Cit-PAB-PNP is a cleavable linker designed for the development of antibody-drug conjugates (ADCs). This compound facilitates the selective delivery of cytotoxic agents to target cells by linking drugs to antibodies through a stable, yet cleavable, bond. Its specific mechanism allows for the release of the drug within the target environment, enhancing therapeutic efficacy while minimizing systemic toxicity. This linker is ideal for applications in cancer research and therapeutic development.

Azide-PEG1-Val-Cit-PABC-OH is a cleavable linker designed for use in antibody-drug conjugates (ADCs). This reagent incorporates an azide functional group, enabling it to participate in copper-catalyzed azide-alkyne cycloaddition (CuAAc) and strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with alkyne-containing molecules. Its key application lies in the synthesis of ADCs, facilitating the precise attachment of drug components to antibodies for targeted therapy.

DBCO-PEG1-OH is an ADC linker designed for effective conjugation in antibody-drug conjugate (ADC) applications. This compound facilitates the synthesis of ADCs by providing a stable and efficient link between monoclonal antibodies and therapeutic agents. Its utility in ADC development supports research in targeted cancer therapies and drug delivery systems.

Azido-PEG3-Val-Cit-PAB-OH is a cleavable antibody-drug conjugate (ADC) linker designed for targeted therapeutic applications. Featuring an azide functional group, it facilitates bioconjugation using copper-catalyzed azide-alkyne cycloaddition (CuAAc) with alkyne-containing compounds, as well as strain-promoted alkyne-azide cycloaddition (SPAAC) with DBCO or BCN moieties. This versatile linker plays a crucial role in the development of ADCs, enhancing their efficacy and therapeutic index in cancer research and treatment.

NHPI-PEG4-C2-Pfp ester is a versatile linker designed for antibody-drug conjugates (ADCs). Its primary mechanism involves facilitating the precise attachment of cytotoxic agents to antibodies, enhancing the efficacy of targeted cancer therapies. This compound is instrumental in streamlining the synthesis of ADCs, thereby advancing research in therapeutic applications and improving treatment precision in oncology.

N-Boc-N-bis(PEG4-OH) is a PEG-based linker designed for use in PROTAC (proteolysis-targeting chimera) synthesis. This cleavable linker also serves as a versatile component for the development of antibody-drug conjugates (ADCs). Due to its unique structure, it facilitates targeted drug delivery and enhances the efficacy of therapeutic agents in various biological applications.

Cyclooctyne-O-amido-PEG3-PFP ester is a non-cleavable linker designed for antibody-drug conjugate (ADC) synthesis. Utilizing click chemistry, this reagent contains an alkyne group that facilitates copper-catalyzed azide-alkyne cycloaddition (CuAAc) with azide-containing molecules. It's ideal for researchers developing targeted therapeutics, enabling precise conjugation with reduced off-target effects.

Azido-PEG5-Ala-Ala-Asn-PAB is a cleavable linker designed for use in antibody-drug conjugates (ADCs). This 5 unit PEG-based reagent features an azide group that enables its application in click chemistry, specifically through copper-catalyzed azide-alkyne cycloaddition (CuAAc) with alkyne-containing compounds. It is also suitable for strain-promoted azide-alkyne cycloaddition (SPAAC) reactions with DBCO or BCN functionalized molecules, facilitating efficient conjugation in the development of targeted therapeutics.

HX20111 is a versatile ADC linker designed for the synthesis of antibody-drug conjugates (ADCs). This compound facilitates the stable attachment of therapeutic agents to antibodies, enhancing targeted delivery and efficacy in cancer treatment. Its utilization in ADC development can contribute to improved selectivity and reduced systemic toxicity in research applications.

Bis-PEG7-acid is a polyethylene glycol (PEG) based linker specifically designed for use in the synthesis of PROTACs (proteolysis-targeting chimeras). This compound enhances the solubility and stability of the PROTAC molecules, facilitating targeted protein degradation. Its application in chemical biology supports research focused on developing novel therapeutics through targeted ubiquitination pathways.

Mal-amido-PEG3-C1-PFP ester serves as a non-cleavable linker for antibody-drug conjugates (ADCs), characterized by a three-unit polyethylene glycol (PEG) structure. This reagent enhances the solubility and stability of ADCs, facilitating improved pharmacokinetics and biodistribution. Its application in the development of targeted therapies allows for effective delivery of cytotoxic agents to specific cancer cells while minimizing off-target effects.

Ald-Ph-amido-PEG2-C2-Pfp ester is a non-cleavable PEG linker designed specifically for antibody-drug conjugates (ADCs). This 2-unit polyethylene glycol (PEG) linker facilitates efficient conjugation between antibodies and therapeutic agents, enhancing the stability and bioavailability of the conjugated compound. Its application in ADCs allows for targeted delivery of cytotoxic agents, thereby improving therapeutic efficacy while minimizing systemic toxicity.

Me-Tet-PEG9-COOH is an ADC linker featuring a tetrazine motif for targeted conjugation. This compound facilitates a specific inverse electron demand Diels-Alder (iEDDA) reaction with trans-cyclooctene (TCO) moieties, enabling efficient bioconjugation applications. Its hydrophilic PEG spacer enhances solubility and stability, making it suitable for antibody-drug conjugate research and development, particularly in targeted therapy strategies.

Fmoc-N-methyl-PEG3-CH2CH2COOH is a PEG-based cleavable linker utilized in the synthesis of antibody-drug conjugates (ADCs). This compound facilitates the effective transport of drug payloads to target cells, enhancing therapeutic efficacy while minimizing off-target effects. Additionally, it serves as a versatile linker in the development of PROTACs (proteolysis-targeting chimeras), supporting research in targeted protein degradation and drug discovery applications.

Propargyl-O-C1-amido-PEG2-C2-NHS ester is a non-cleavable linker designed for antibody-drug conjugates (ADCs) that facilitates precise molecular attachment. This 2-unit PEG linker incorporates an alkyne group, enabling the copper-catalyzed azide-alkyne cycloaddition (CuAAC) with azide-containing compounds. Its unique structure supports enhanced stability and bioactivity in various biochemical applications, making it a valuable reagent for research in targeted therapeutics and drug delivery systems.

N3-PEG3-C2-PFP ester is a non-cleavable 3-unit PEG linker designed for the synthesis of antibody-drug conjugates (ADCs). This compound features an azide functionality, enabling it to participate in copper-catalyzed azide-alkyne cycloaddition reactions (CuAAc) with alkyne-containing molecules. Additionally, it can engage in strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with DBCO or BCN modified compounds. N3-PEG3-C2-PFP ester is a versatile tool for enhancing the stability and efficacy of ADCs in therapeutic research applications.

Ald-Ph-amido-PEG1-C2-NHS ester is a non-cleavable polyethylene glycol (PEG) linker designed for antibody-drug conjugation (ADC) applications. This 1-unit PEG derivative facilitates the stable attachment of drugs to antibodies, enhancing the therapeutic efficacy and specificity of conjugates. Its robust chemical properties make it suitable for a variety of research applications in the development of targeted therapies.

NO2-SPP-sulfo is a cleavable linker designed for antibody-drug conjugate (ADC) synthesis. This compound facilitates the targeted delivery of therapeutic agents, enhancing the efficacy and safety of drug formulations. Its unique properties enable selective release of the drug component in the target cells, making it a vital tool in cancer research and therapeutic development.

N-Succinimidyloxycarbonylpropyl methanethiosulfonate is a non-cleavable linker designed for the synthesis of antibody-drug conjugates (ADCs). It features a methanethiosulfonate moiety that facilitates stable attachment between antibodies and drug payloads, ensuring effective delivery and enhanced therapeutic efficacy. This compound is particularly valuable in bioconjugation applications aimed at targeted cancer therapies and other therapeutic strategies.

PDB-Pfp is a cleavable linker designed for the formation of antibody-drug conjugates (ADCs). It facilitates the selective release of the cytotoxic drug upon internalization by target cells, enhancing the therapeutic efficacy of ADCs. This reagent is essential for researchers developing targeted cancer therapies and studying the mechanisms of antibody-drug conjugate action.

Mal-amido-PEG8-val-gly-PAB-OH is a cleavable polyethylene glycol (PEG) linker designed for use in the development of antibody-drug conjugates (ADCs). This 8-unit PEG structure enhances solubility and stability while facilitating controlled drug release. Its applications include targeted delivery of cytotoxic agents to specific cells, making it a valuable tool for cancer therapeutics and research in drug conjugation technologies.

Propargyl-PEG9-bromide is a PEG-based linker utilized in the synthesis of PROTACs and antibody-drug conjugates (ADCs). This non-cleavable linker facilitates the targeted delivery of therapeutics through its unique click chemistry capabilities, featuring an alkyne group suitable for copper-catalyzed azide-alkyne cycloaddition (CuAAc). Its applications extend to enhancing drug efficacy and specificity in chemical biology and therapeutic development.

Ald-Ph-amido-PEG11-NH-Boc is a non-cleavable 11-unit polyethylene glycol (PEG) linker designed for use in the synthesis of antibody-drug conjugates (ADCs). This compound facilitates the stable attachment of cytotoxic agents to antibodies, enhancing the therapeutic efficacy of ADCs while maintaining their specificity towards target cells. Its unique structure supports improved solubility and biocompatibility, making it a valuable tool in cancer research and drug development.

Fmoc-Ala-Ala-Asn-PABC-PNP is a peptide-cleavable linker designed for antibody-drug conjugates (ADCs). This compound features a unique functionality that facilitates the release of cytotoxic drugs upon enzymatic cleavage. It is ideal for applications in targeted cancer therapy research, enabling the development of more effective and safer treatment options through selective drug delivery.

Boc-Aminooxy-PEG2-bromide is a cleavable 2 unit polyethylene glycol (PEG) linker designed for use in the synthesis of antibody-drug conjugates (ADCs). This linker facilitates the attachment of drug molecules to antibodies, promoting targeted delivery and enhanced therapeutic efficacy. Its application is critical in the development of innovative ADCs for cancer therapy and other diseases, enabling selective release of cytotoxic agents in tumor microenvironments.

N-(Iodoacetamido)-Doxorubicin is a cleavable linker designed for the synthesis of antibody-drug conjugates (ADCs). This reagent enables the targeted delivery of doxorubicin, a potent chemotherapeutic agent, by covalently binding to antibodies, thereby enhancing the therapeutic efficacy and specificity of the conjugate. Its unique bioconjugation properties make it a valuable tool in cancer research, particularly in the development of innovative ADC therapies.

THP-SS-PEG1-Tos is a cleavable linker designed for use in antibody-drug conjugates (ADCs), featuring a polyethylene glycol (PEG) unit. This linker facilitates the selective release of cytotoxic agents in targeted therapies, enhancing the therapeutic index of ADCs. Its unique properties make it suitable for applications in cancer research and drug development, providing a versatile tool for improving the efficacy of antibody-mediated treatments.

Fmoc-Val-Ala-Gly is a cleavable linker specifically designed for antibody-drug conjugate (ADC) applications. This compound facilitates conjugation with antibodies, such as Trastuzumab, enabling the targeted delivery of cytotoxic agents to cancer cells. Its structural attributes promote effective release of the drug upon internalization, making it a valuable reagent for ADC development in cancer research.

Tr-PEG5-OH is a non-cleavable polyethylene glycol (PEG) linker designed for use in the synthesis of antibody-drug conjugates (ADCs). Comprising five PEG units, this versatile linker facilitates the conjugation of antibodies to cytotoxic drugs, enhancing the therapeutic efficacy and selectivity of ADCs. Additionally, Tr-PEG5-OH serves as a PEG-based PROTAC linker, enabling the development of proteolysis-targeting chimeras for targeted protein degradation studies.

Fmoc-Gly3-Val-Cit-PAB-PNP is a cleavable four-unit PEG linker designed for the synthesis of antibody-drug conjugates (ADCs). This linker is engineered to enhance the stability and efficacy of ADCs, facilitating precise drug delivery to targeted cells. Its unique structure allows for controlled release of the cytotoxic agent, making it suitable for applications in cancer therapeutics and targeted drug delivery research.

m-PEG7-CH2CH2CHO is a non-cleavable linker primarily designed for the development of antibody-drug conjugates (ADCs). This PEG-based compound facilitates efficient conjugation of cytotoxic payloads to antibodies, enhancing targeted delivery and therapeutic efficacy. Additionally, m-PEG7-CH2CH2CHO serves as a versatile linker in the synthesis of PROTACs, supporting research into targeted protein degradation mechanisms.

Azidoethyl-SS-propionic acid is a cleavable linker designed for the synthesis of antibody-drug conjugates (ADCs). This compound features an azide group that facilitates click chemistry through copper-catalyzed azide-alkyne cycloaddition (CuAAc) with alkyne-containing molecules. Additionally, it can participate in strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with DBCO or BCN functionalized compounds, making it valuable for targeted drug delivery and bioconjugation applications in research.

m-PEG4-Boc is a cleavable polyethylene glycol (PEG) linker with four ethylene glycol units, designed for use in the synthesis of antibody-drug conjugates (ADCs) and Proteolysis Targeting Chimeras (PROTACs). This versatile linker facilitates the development of ADCs by enabling site-specific conjugation, while also serving as a crucial component in PROTAC design for targeted protein degradation. Its functional properties contribute to the effectiveness and stability of various bioconjugates in chemical biology research.

Fmoc-PEG4-Ala-Ala-Asn-PAB is a cleavable ADC linker composed of a 4-unit polyethylene glycol (PEG) backbone. This reagent facilitates the synthesis of antibody-drug conjugates (ADCs) by enabling the selective attachment of therapeutic agents to antibodies. Its design contributes to improved solubility and stability of ADCs, making it a valuable tool in targeted drug delivery research and development.

Mal-C5-N-bis(PEG2-C2-acid) is a versatile linker specifically designed for the formulation of antibody-drug conjugates (ADCs). This compound facilitates efficient conjugation through its maleimide functionality, ensuring stable attachment to thiol groups present on antibodies. Its unique PEG-based structure enhances solubility and biocompatibility, making it ideal for improving the pharmacokinetic properties of ADCs in various therapeutic research applications.

Ald-Ph-amido-PEG11-C2-NH2 is a non-cleavable 11-unit polyethylene glycol (PEG) linker designed for use in antibody-drug conjugate (ADC) synthesis. This versatile linker facilitates the stable attachment of cytotoxic agents to antibodies, enhancing the therapeutic efficacy of ADCs while minimizing systemic toxicity. Its design is optimized for applications in targeted cancer therapy research, allowing for precise drug delivery to malignant tissues.

LC-SMCC is a versatile ADC linker that facilitates the conjugation of drugs to antibodies, enabling the development of antibody-drug conjugates (ADCs). Its primary mechanism involves the formation of stable thioether bonds through the reaction with thiol groups on the antibody. This compound is crucial for enhancing targeted delivery and efficacy of therapeutic agents while minimizing systemic toxicity, making it an essential tool in cancer research and drug development.

MC(C5)-Val-Cit is a cleavable linker designed for use in the synthesis of antibody-drug conjugates (ADCs). It facilitates the selective release of cytotoxic agents upon internalization, ensuring targeted delivery to tumor cells. This linker is particularly valuable for researchers developing ADCs to enhance therapeutic efficacy while minimizing off-target effects.

GDP-L-Fuc-PEG4-BCN is a cleavable linker designed for use in antibody-drug conjugates (ADCs). This linker facilitates the efficient conjugation of antibodies with cytotoxic drugs, enhancing targeted delivery to tumor cells. Its incorporation allows for controlled release of therapeutic agents upon internalization, making it suitable for cancer research and the development of innovative ADC therapeutics.

Aloc-D-Ala-Phe-Lys(Aloc)-PAB-PNP is a cleavable linker specifically designed for antibody-drug conjugate (ADC) synthesis. This compound facilitates the targeted delivery of cytotoxic agents by covalently attaching them to antibodies, ensuring selective action on tumor cells. Its unique structure allows for controlled release of the drug in the target environment, making it a key component in ADC development and research applications focused on cancer therapeutics.

1,6-Bis(mesyloxy)hexane is a cleavable linker designed for use in the synthesis of antibody-drug conjugates (ADCs). It facilitates the precise attachment of therapeutic agents to antibodies, enhancing targeted delivery in cancer therapy. Its design allows for effective cleavage in the target environment, thus promoting the selective release of cytotoxic drugs and improving therapeutic efficacy in research applications.

Tup hydrochloride is a cleavable linker for antibody-drug conjugates (ADCs). It facilitates the selective release of cytotoxic agents in targeted therapy, enhancing therapeutic efficacy by ensuring the release of the drug in the vicinity of the target cells. This compound is particularly useful in the development and optimization of ADCs for cancer treatment research.